Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Joerg Moeller

Shire Basingstoke

Shire pitching at adult ADHD product launch in 2017

Will have to first trial formulation in children to appease FDA

EISAI

Eisai’s thyroid cancer drug Lenvima nears EU approval

Positive recommendation by the CHMP could see the orphan drug used in Europe within three months

Shire Basingstoke

Shire links with US hospital for rare disease research

Willwork with Cincinnati Children's Hospital Medical Centre novel therapies

- PMLiVE

Bayer’s Eylea cleared for wider use in Europe

Macular oedema treatment reached €759m in sales last year

Shire Basingstoke

Shire boosts orphan drug pipeline with Meritage Pharma deal

Firm will also acquire global rights to Meritage’s phase III OBS compound

- PMLiVE

UK doctors call on NHS to use Avastin for wet AMD

Controversial practice of using the drug off-label could save the health service £102m

- PMLiVE

Werner Baumann to replace Brandicourt at Bayer

Will assume the role of chairman after the former boss jumped ship to Sanofi

- PMLiVE

Rumour mill intensifies around Bayer’s Brandicourt for Sanofi

Could be named Sanofi chief executive as soon as next March

- PMLiVE

Valeant and Shire said to be evaluating potential Salix bids

Valeant currently in final stages of Provenge acquisition

- PMLiVE

Monica Seles to front Shire’s binge eating disorder campaign

Tennis star experienced condition at height of her success

- PMLiVE

Shire gets FDA nod for first binge-eating treatment

Vyvanse already available as ADHD treatment

- PMLiVE

Relief for Shire as FDA clears NPS’ Natpara

Drug was a key interest as part of NPS takeover

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links